A
115.07
0.00 (0.00%)
| Previous Close | 115.07 |
| Open | 115.07 |
| Avg. Volume (3M) | 1,446,171 |
| Market Cap | 6,732,325,376 |
| Price / Sales | 290.72 |
| Price / Book | 16.73 |
| 52 Weeks Range |
| Profit Margin | -211.46% |
| Operating Margin (TTM) | -847.56% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | -79.30% |
| Total Debt/Equity (MRQ) | 12.76% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -114.70 M |
| Levered Free Cash Flow (TTM) | -10.43 M |
| Return on Assets (TTM) | -16.69% |
| Return on Equity (TTM) | -35.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Arcellx, Inc. | Mixed | Bullish |
AIStockmoo Score
0.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.00 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 14.50% |
| % Held by Institutions | 102.08% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |